Obsidian Therapeutics, Inc. (OBX) stock
OBXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$12.00−0.15 (-1.23%)
Close on Nov 20, 2026Market cap $741.28MP/E –Yield –
Obsidian Therapeutics net income
Net income is the profit left for shareholders after every expense, interest and tax.
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$50.66M | – |
| Q2 FY2026 | Jun 30, 2026 | -$25.86M | – |
| Q1 FY2026 | Apr 10, 2026 | -$19.63M | – |
| Q3 FY2025 | Sep 30, 2025 | -$28.47M | – |
| Q2 FY2025 | Jun 30, 2025 | -$26.90M | – |
| Q1 FY2025 | Mar 31, 2025 | -$24.99M | – |
See a number that looks wrong?